Home / News / World News / Article /
China approves third COVID-19 vaccine for clinical trials
Updated On: 25 April, 2020 12:23 PM IST | Beijing | PTI
An "inactivated" vaccine consists of virus particles, bacteria, or other pathogens that have been grown in culture and then lose disease producing capacity

Medical personnel taking swab samples of a man for nucleic acid testing as part of COVID-19 pandemic measures, at a health services centre. Pic/ AFP
China has approved its third coronavirus vaccine for the second phase of clinical trials as it reported 12 new COVID-19 cases, taking the total number of infections in the country to 82,816. China has approved three coronavirus vaccines, including the one developed by Chinese military, the People's Liberation Army (PLA) for clinical trials. An "inactivated" vaccine developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and the Wuhan Institute of Virology (WIV) started its clinical trials, state-run Xinhua news agency reported.
An "inactivated" vaccine consists of virus particles, bacteria, or other pathogens that have been grown in culture and then lose disease producing capacity. In contrast, live vaccines use pathogens that are still alive. WIV has been in the eye of the storm in recent weeks as US President Donald Trump and top American officials alleged that the coronavirus may have escaped from there and demanded a probe into it. An official of the WIV denied it, terming the allegation "entirely based on speculation".

